Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2026-02-23 @ 7:57 AM
Study NCT ID:
NCT02387957
Status:
TERMINATED
Last Update Posted:
2024-10-30
First Post:
2015-03-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
Sponsor:
Ophthotech Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-04-26
Start Date Type:
ACTUAL
Primary Completion Date:
2017-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-01
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-09
First Submit QC Date:
None
Study First Post Date:
2015-03-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-10-23
Results First Submit QC Date:
None
Results First Post Date:
2019-03-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-19
Last Update Post Date:
2024-10-30
Last Update Post Date Type:
ACTUAL